Stifel Financial
RNAC icon

Stifel Financial’s Cartesian Therapeutics RNAC Stock Holding History

Stifel Financial’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-363
Closed -$26K – 2929
2020
Q1 		$26K Sell
363
-200
-36% -$19.3K ﹤0.01% 2713
2019
Q4 		$40K Buy
563
+166
+42% +$8.01K ﹤0.01% 2927
2019
Q3 		$21K Sell
397
-80
-17% -$4.25K ﹤0.01% 2827
2019
Q2 		$26K Sell
477
-321
-40% -$21.9K ﹤0.01% 2883
2019
Q1 		$55K Buy
+798
New +$50.6K ﹤0.01% 2737

Other funds holding RNAC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Stifel Financial's RNAC Position: Q2 2020 in Review

Stifel Financial sold out of Cartesian Therapeutics (RNAC) in Q2 2020, closing a stake of 363 shares — an estimated $26K sold.

Stifel Financial first reported a position in RNAC in Q1 2019 and held it in 5 quarters. The position peaked at $55K in Q1 2019. 81 funds tracked by Wall St. Rank hold RNAC as of Q2 2020.

  • Stifel Financial reported no remaining Cartesian Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Stifel Financial sold 363 Cartesian Therapeutics shares in Q2 2020, an estimated $26K.
  • Stifel Financial first reported a position in Cartesian Therapeutics in Q1 2019 and held it in 5 quarters.
  • Stifel Financial's Cartesian Therapeutics position peaked at $55K in Q1 2019.
  • 81 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2020.

Based on Stifel Financial's 13F filing for Q2 2020, filed 14 Aug 2020.